专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2005075001A1 MEDICATED POLYURETHANE FOAMS 审中-公开
标题翻译：药用聚氨酯泡沫
公开(公告)号：WO2005075001A1
公开(公告)日：2005-08-18
申请号：PCT/GB2005/000359
申请日：2005-02-02
申请人： ETHICON, INC. , ADDISON, Deborah , ESSLER, Alicia , LAMB, Bruce
发明人： ADDISON, Deborah , ESSLER, Alicia , LAMB, Bruce
IPC分类号： A61L15/26
CPC分类号： A61L15/425 , A61L15/26 , C08L75/04
摘要： A method of forming a polyurethane foam suitable for use as a wound-contacting layer, said method comprising: mixing 1 part by weight of an isocyanate-capped prepolymer having from 0.5 to 1.2 meq NCO groups/g with from 0.4 to 1.0 parts by weight of water in the presence of from 0.05 to 0.4 parts by weight of a C1 to C3 monohydric alcohol to form a foamed product; followed by treating the foamed product with a dispersion of a therapeutic agent and drying the treated foamed product. Also provided are medicated polyurethane foams obtainable by the method of the invention, and wound dressings comprising such foams.
摘要翻译：一种形成适合用作伤口接触层的聚氨酯泡沫体的方法，所述方法包括：将1重量份具有0.5至1.2meq NCO基团/ g的异氰酸酯封端的预聚物与0.4至1.0重量份的水，在0.05至0.4重量份的C1至C3一元醇的存在下形成发泡产品; 然后用处理剂的分散体处理发泡产物并干燥经处理的发泡产品。还提供了可通过本发明的方法获得的药用聚氨酯泡沫和包含这种泡沫的伤口敷料。

2. 发明申请

WO2019246483A1 GENETICALLY MODIFIED MOUSE MODELS OF ALZHEIMER'S DISEASE 审中-公开
公开(公告)号：WO2019246483A1
公开(公告)日：2019-12-26
申请号：PCT/US2019/038401
申请日：2019-06-21
申请人： THE JACKSON LABORATORY , INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION , SAGE BIONETWORKS , RIZZO, Stacey , WILLIAMS, Harriet , LAMB, Bruce , TERRITO, Paul , OBLAK, Adrian
发明人： RIZZO, Stacey , WILLIAMS, Harriet , LAMB, Bruce , TERRITO, Paul , OBLAK, Adrian , HOWELL, Gareth , CARTER, Gregory , SASNER, Michael , LOGSDON, Ben , MANGRAVITE, Lara , GRAHAM, Leah
IPC分类号： A01K67/027 , C07K14/775 , C12N15/09
摘要： The present disclosure provides a genetically modified mouse comprising a genomic nucleic acid encoding human APOE4, a genomic nucleic acid encoding mouse TREM2 modified to include a R47H substitution, and at least one genomic modification selected from the group consisting of: (a) a genomic nucleic acid encoding mouse ABCA7 modified to include an A 1541 G substitution; (b) a genomic nucleic acid encoding mouse APP modified to include G601R, F606Y, and R609H substitutions; (c) a genomic nucleic acid encoding mouse PLCG2 modified to include a M28L substitution; (d) a genomic nucleic acid encoding mouse MTHFR modified to include a A262V substitution; (e) an inactivated Ceacaml allele; and (f) an inactivated ΙĮ1rap allele. Methods of producing the genetically modified mouse and methods of using the genetically modified mouse are also provided.

3. 发明申请

WO2017027512A1 USE OF LAQUINIMOD TO TREAT TRAUMATIC BRAIN INJURY 审中-公开
标题翻译：使用LAQUINIMOD治疗TRAUMATIC脑损伤
公开(公告)号：WO2017027512A1
公开(公告)日：2017-02-16
申请号：PCT/US2016/046169
申请日：2016-08-09
申请人： TEVA PHARMACEUTICAL INDUSTRIES LTD. , LAMB, Bruce , KATSUMOTO, Atsuko
发明人： LAMB, Bruce , KATSUMOTO, Atsuko
IPC分类号： A61K31/47 , A61K31/4704 , C07D215/56 , C07D215/227
CPC分类号： A61K31/4704 , A61K45/06 , C07D215/227 , C07D215/56
摘要： This application provides for a method of treating a subject suffering from traumatic brain injury, the method comprising periodically administering to the subject an amount of laquinimod or pharmaceutically acceptable salt thereof effective to treat the subject. This application also provides use of laquinimod in the manufacture of a medicament for treating a subject suffering from traumatic brain injury. This application also provides laquinimod for use in treating a subject suffering from traumatic brain injury. This application also provides use of laquinimod in treating a subject suffering from traumatic brain injury. This application also provides a pharmaceutical composition comprising laquinimod for use in treating a subject suffering from traumatic brain injury. This application also provides a pharmaceutical oral unit dosage form of laquinimod for use in treating a subject suffering from traumatic brain injury.
摘要翻译：本申请提供了治疗患有创伤性脑损伤的受试者的方法，该方法包括向受试者定期施用一定量的有效治疗受试者的拉喹莫德或其药学上可接受的盐。本申请还提供了拉喹莫德在制备用于治疗患有创伤性脑损伤的受试者的药物中的用途。本申请还提供了用于治疗患有创伤性脑损伤的受试者的拉喹莫德。本申请还提供了使用拉喹莫德治疗患有创伤性脑损伤的受试者。本申请还提供了包含用于治疗患有创伤性脑损伤的受试者的拉喹莫德的药物组合物。本申请还提供了用于治疗患有创伤性脑损伤的受试者的拉喹莫德的药物口服单位剂量形式。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式